RXI Pharmaceuticals Corporation

Westborough, MA 01581

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.47MM
First Award Date 07/15/10
Most Recent Award Date 09/25/12

Key Personnel

Last Name Name Awards Contact
Khvorova Anastasia Khvorova 3
Pavco Pamela Pavco 1
Bulock Karen G Bulock 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/25/12 - 02/28/13

DESCRIPTION (provided by applicant): The study of retinoblastoma, a childhood tumor, has provided numerous insights into cancer biology. Perhaps most significantly, this work has revealed that cancers can develop in response to mutations in tumor suppressor genes. Tumor suppressor mutations account for ~80% of all cancer mutations, but unlike ac...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/12 - 05/31/13

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 07/01/11 - 06/30/12

DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability to apply this technology to human afflictions, in particular, diseas...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/15/11 - 07/31/13

DESCRIPTION (provided by applicant): Project Summary / Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the central nervous system. Degeneration of the motor neurons results in paralysis and eventual death, usually due to respiratory failure. In a subset of cases, ALS is cause...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 07/15/10 - 06/30/11

DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability to apply this technology to human afflictions, in particular, diseas...